• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials
CONCLUSIONS: Roxadustat was more effective than placebo at increasing hemoglobin in patients with non-dialysis-dependent CKD and anemia, while decreasing transfusion rate and being noninferior to placebo with respect to risk of MACE.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis, NCT01750190; Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS), NCT01887600; Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not ...
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 7, 2021 Category: Urology & Nephrology Authors: Robert Provenzano Lynda Szczech Robert Leong Khalil G Saikali Ming Zhong Tyson T Lee Dustin J Little Mark T Houser Lars Frison John Houghton Thomas B Neff Source Type: research

Major Adverse Renal and Cardiovascular Events following Intra-Arterial Contrast Media Administration in Hospitalized Patients with Comorbid Conditions
Conclusion: Intra-arterial administration using IOCM in at-risk patients is associated with lower rates of MARCE than the use of LOCM. This difference is especially apparent in patients with a combination of CKD 3 –4 and diabetes and in patients with CTO, providing real-world data validation with meaningful NNT in favor of IOCM.Cardiorenal Med
Source: Cardiorenal Medicine - August 12, 2021 Category: Urology & Nephrology Source Type: research

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials
CONCLUSIONS: Roxadustat was more effective than placebo at increasing hemoglobin in patients with non-dialysis-dependent CKD and anemia, while decreasing transfusion rate and being noninferior to placebo with respect to risk of MACE.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis, NCT01750190; Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS), NCT01887600; Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not ...
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 7, 2021 Category: Urology & Nephrology Authors: Robert Provenzano Lynda Szczech Robert Leong Khalil G Saikali Ming Zhong Tyson T Lee Dustin J Little Mark T Houser Lars Frison John Houghton Thomas B Neff Source Type: research

Acute kidney injury and risk of cardiovascular outcomes: A nationwide cohort study
CONCLUSION: Non-selected patients aged 50 years or above with AKI during admission had significantly higher one-year risk of cardiovascular event or death, especially, but not only due to heart failure, independent of age and eGFR.PMID:34489123 | DOI:10.1016/j.nefro.2021.06.007
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - September 7, 2021 Category: Urology & Nephrology Authors: Philip Andreas Schytz Paul Blanche Anders Bonde Nissen Christian Torp-Pedersen Gunnar H Gislason Karl Emil Nelveg-Kristensen Kristine Hommel Nicholas Carlson Source Type: research

Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target
Chronic kidney disease (CKD) is present in almost 10% of the world population and is associated with excess mortality and morbidity. Reduced glomerular filtration rate and the presence and extent of proteinuria, key domains of CKD, have both been shown to be strong and independent risk factors for cardiovascular disease. Patients with kidney failure requiring dialysis are at highest risk for cardiovascular events, for example, stroke or myocardial infarction, and of developing chronic cardiovascular conditions, such as heart failure.
Source: Kidney International - September 30, 2021 Category: Urology & Nephrology Authors: John Eikelboom, J ürgen Floege, Ravi Thadhani, Jeffrey I. Weitz, Wolfgang C. Winkelmayer Tags: review Source Type: research

Association of peridialytic, intradialytic, scheduled interdialytic and ambulatory BP recordings with cardiovascular events in hemodialysis patients
CONCLUSIONS: Averaged intradialytic and scheduled home BP measurements (but not pre-dialysis readings) display similar prognostic associations with 44-h ambulatory BP in hemodialysis patients and represent valid metrics for hypertension management in these individuals.PMID:34988941 | DOI:10.1007/s40620-021-01205-9
Source: Journal of Nephrology - January 6, 2022 Category: Urology & Nephrology Authors: Fotini Iatridi Marieta P Theodorakopoulou Antonios Karpetas Athanasios Bikos Artemios G Karagiannidis Maria-Eleni Alexandrou Ioannis Tsouchnikas Christopher C Mayer Anna-Bettina Haidich Aikaterini Papagianni Gianfranco Parati Pantelis A Sarafidis Source Type: research

Mitochondrial deacetylase Sirt3 in vascular dysfunction and hypertension
Purpose of review Hypertension is a multifactorial disorder involving perturbations of the vasculature, the kidney, and the central nervous system. Hypertension represents a major risk factor for stroke, myocardial infarction, and heart failure. Despite treatment with multiple drugs, 37% of hypertensive patients remain hypertensive, likely due to the mechanisms contributing to blood pressure elevation that are not affected by current treatments. This review focuses on recently described novel role of mitochondrial deacetylase Sirt3 in vascular dysfunction and hypertension. Recent findings In the past several yea...
Source: Current Opinion in Nephrology and Hypertension - February 2, 2022 Category: Urology & Nephrology Tags: PATHOPHYSIOLOGY OF HYPERTENSION: Edited by Nancy J. Brown Source Type: research

A population cohort analysis of English transplant centers indicates major adverse cardiovascular events after kidney transplantation.
Major adverse cardiovascular event (MACE) rates immediately after kidney transplantation remain uncertain due to heterogeneous reporting in the literature. To clarify this, we retrospectively studied every eligible kidney transplant procedure performed in England between April 1, 2002 and March 31. 2018 with follow-up through August 31, 2019. The primary outcome of interest was MACE broadly defined as any hospital admission with myocardial infarction, stroke, unstable angina, heart failure, any coronary revascularisation procedure and/or any cardiovascular death.
Source: Kidney International - June 15, 2022 Category: Urology & Nephrology Authors: Benjamin Anderson, Muhammad Qasim, Felicity Evison, Suzy Gallier, Jonathan N. Townend, Charles J. Ferro, Adnan Sharif Tags: clinical investigation Source Type: research

Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain
CONCLUSIONS: In Spain, CKD population is older and comorbidities, including diabetes and heart failure, are common. Cardiovascular and renal outcomes are frequent. There is room for improvement in CKD management, particularly through the use of drugs with proven cardiovascular and renal benefit.PMID:36165157 | DOI:10.1016/j.nefroe.2022.01.008
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - September 27, 2022 Category: Urology & Nephrology Authors: Carlos Escobar Unai Aranda Beatriz Palacios Margarita Capel Antoni Sicras Aram Sicras Antonio Hormigo Roberto Alc ázar Nicol ás Manito Manuel Botana Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11